VTP-27999 has been used in trials studying the basic science of Renal Function.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Sodium phosphate, monobasic | The risk or severity of nephrotoxicity can be increased when VTP-27999 is combined with Sodium phosphate, monobasic. |
| Valsartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Valsartan. |
| Olmesartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Olmesartan. |
| Losartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Losartan. |
| Candesartan cilexetil | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Candesartan cilexetil. |
| Eprosartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Eprosartan. |
| Telmisartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Telmisartan. |
| Irbesartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Irbesartan. |
| Forasartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Forasartan. |
| Saprisartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Saprisartan. |
| Tasosartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Tasosartan. |
| Saralasin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Saralasin. |
| Azilsartan medoxomil | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Azilsartan medoxomil. |
| Fimasartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Fimasartan. |
| Candesartan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Candesartan. |
| Sparsentan | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when VTP-27999 is combined with Sparsentan. |